Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Carolyn Lane
Manager, Research Laboratory
Cancer Center Division
Overview
Research
More
Collaboration
(20)
Fernanda Sanchez Borchardt
Mutual work: 4 Proposals﹒2 Grants
Collaboration Details
Sylvia DeCero
Mutual work: 2 Grants﹒4 Proposals
Collaboration Details
Jennifer Segar
Mutual work: 2 Grants
Collaboration Details
Sima Ehsani Chimeh
Mutual work: 2 Grants
Collaboration Details
Niyuri Fleming
Mutual work: 2 Grants﹒5 Proposals
Collaboration Details
Page 1 of 4
Previous page
Next page
Grants
(5)
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women
Active
·
2023
·
$0 / $270.2K
·
External
undefined (CD)
clinical trials,
cancer treatment,
immunotherapy,
chemotherapy,
women's health
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
Active
·
2023
·
$0 / $188.6K
·
External
undefined (CD)
lymphoma,
cancer treatment,
immunotherapy,
clinical trial,
drug combination
A Phase 1/2, Open Label, Dose-Escalation Study Of Oral ORIN1001 With And Without Chemotherapy In The Treatment Of Subjects With Solid Tumors
Active
·
2022
·
$0 / $245.9K
·
External
undefined (CD)
oncology,
clinical trial,
chemotherapy,
solid tumors,
dose escalation
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL114 in Subjects with Non-Hodgkins Lymphoma
Active
·
2022
·
$0 / $236.5K
·
External
undefined (CD)
pharmacokinetics,
oncology,
clinical trial,
safety,
dose escalation
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients with Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy
Active
·
2022
·
$0 / $185.5K
·
External
undefined (CD)
cancer immunotherapy,
metastatic breast cancer,
immunotherapy combinations,
hormone therapy resistance